A randomized controlled trial on the effects of modified Shenling Baizhu Powder on peripheral blood counts and immune function in patients with breast cancer chemotherapy-induced bone marrow suppression and spleen-kidney deficiency syndrome.

INTERVENTION: Control Group:Doxorubicin + cyclophosphamide followed by paclitaxel chemotherapy + placebo;Treatment group:Doxorubicin + cyclophosphamide followed by paclitaxel chemotherapy + modified Shenling Baizhu Powder; CONDITION: Chemotherapy‐induced bone marrow suppression PRIMARY OUTCOME: Peripheral blood count indicators; SECONDARY OUTCOME: Immune function indicators;Traditional Chinese Medicine Syndrome Scoring;Chemotherapy completion rate;Adverse reaction incidence; INCLUSION CRITERIA: (1) Meets the diagnostic criteria for breast cancer: Based on the "Guidelines and Standards for the Diagnosis and Treatment of Breast Cancer by the Chinese Anti‐Cancer Association (2021 Edition)". 1) A painless, hard, poorly defined, and mobile lump appears in the breast; some patients may also experience nipple discharge, nipple retraction, and orange peel‐like changes in the breast skin; 2) Mammography reveals a mass and microcalcifications within the breast; 3) Breast ultrasound shows hypoechoic nodules with uneven echogenicity and irregular shape; 4) Pathological examination of the lesion tissue obtained through core needle biopsy, Mammotome biopsy, or surgical excision biopsy indicates breast cancer. (2) Meets the diagnostic criteria for spleen and kidney deficiency in Traditional Chinese Medicine: Based on the "Consensus on the Diagnosis and Treatment of Breast Cancer Using Integrated Traditional Chinese and Western Medicine". Main symptoms: soreness and we